Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation
K.A. Walsh, G.A. Davis, D. Jr Hayes, R.J. Kuhn, K.A. Weant, J.D. Flynn. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Transpl Infect Dis 2011: 13: 616–621. All rights reserved Study objectives. To compare the pharmacokinetics (PK) of to...
Gespeichert in:
| Veröffentlicht in: | Transplant infectious disease 2011-12, Vol.13 (6), p.616-621 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 621 |
|---|---|
| container_issue | 6 |
| container_start_page | 616 |
| container_title | Transplant infectious disease |
| container_volume | 13 |
| creator | Walsh, K.A. Davis, G.A. Hayes, D. Jr Kuhn, R.J. Weant, K.A. Flynn, J.D. |
| description | K.A. Walsh, G.A. Davis, D. Jr Hayes, R.J. Kuhn, K.A. Weant, J.D. Flynn. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation.
Transpl Infect Dis 2011: 13: 616–621. All rights reserved
Study objectives. To compare the pharmacokinetics (PK) of tobramycin in patients with cystic fibrosis (CF) before and after bilateral lung transplantation, in order to evaluate optimal dosing practices post transplant.
Design. Retrospective, single‐center, chart review study, in which tobramycin concentrations from CF patients were used to calculate PK parameters, including elimination rate constant, half‐life, volume of distribution (Vd), area under the curve (AUC), and clearance before and after lung transplantation.
Setting. Medical school‐affiliated teaching hospital.
Patients. Eight patients with CF, who received a bilateral lung transplant from January 1, 2005 through August 1, 2009 (4 males, 4 females; mean age 26.3 years).
Interventions. None.
Main results. Sixty‐nine sets of pre‐ (n=52) and post transplant (n=17) tobramycin concentrations were available. PK parameters were significantly altered post transplant. Elimination rate constant decreased 38% from 0.26±0.1 to 0.16±0.1 h‐1 (P |
| doi_str_mv | 10.1111/j.1399-3062.2011.00651.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_918578397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>918578397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4051-9c8bb5d06a755572589baa1a5470f0f19c40e557675a40ecdda739110845b91d3</originalsourceid><addsrcrecordid>eNqNUMtuGyEURVGr2En7CxG7rGYCM8MwSN1UbppGslypch87dGGYBHseDmDZ_vsyduJ12NwjzuPCQQhTktJ47lYpzYVIclJmaUYoTQkpGU33F2h6Jj4ccZVkGc8n6Mr7FSGUi0Jcokk2AlJkU9QuB-WgO2jb480zuA70sLa9CVZ7PN5BsKYPHu9seMb64COBG6vc4K3HyjSDMxj6GkMTjMPKthAntLjd9k84OOj9poU-xJih_4Q-NtB68_l1XqPf3--Xsx_J_OfD4-zrPNEFYTQRulKK1aQEzhjjGauEAqDACk4a0lARZSYSJWcQka5r4LmglFQFU4LW-TW6PeVu3PCyNT7Iznpt2vgQM2y9FLRivMoFj8rqpNTxQ96ZRm6c7cAdJCVyrFqu5NioHBuVY9XyWLXcR-vN65Kt6kx9Nr51GwVfToKdbc3h3cFy-fgtgmhPTnbrg9mf7eDWsuQ5Z_Lv4kEuF4t_pPizkL_y_7_2nbI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>918578397</pqid></control><display><type>article</type><title>Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Walsh, K.A. ; Davis, G.A. ; Hayes, D. Jr ; Kuhn, R.J. ; Weant, K.A. ; Flynn, J.D.</creator><creatorcontrib>Walsh, K.A. ; Davis, G.A. ; Hayes, D. Jr ; Kuhn, R.J. ; Weant, K.A. ; Flynn, J.D.</creatorcontrib><description>K.A. Walsh, G.A. Davis, D. Jr Hayes, R.J. Kuhn, K.A. Weant, J.D. Flynn. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation.
Transpl Infect Dis 2011: 13: 616–621. All rights reserved
Study objectives. To compare the pharmacokinetics (PK) of tobramycin in patients with cystic fibrosis (CF) before and after bilateral lung transplantation, in order to evaluate optimal dosing practices post transplant.
Design. Retrospective, single‐center, chart review study, in which tobramycin concentrations from CF patients were used to calculate PK parameters, including elimination rate constant, half‐life, volume of distribution (Vd), area under the curve (AUC), and clearance before and after lung transplantation.
Setting. Medical school‐affiliated teaching hospital.
Patients. Eight patients with CF, who received a bilateral lung transplant from January 1, 2005 through August 1, 2009 (4 males, 4 females; mean age 26.3 years).
Interventions. None.
Main results. Sixty‐nine sets of pre‐ (n=52) and post transplant (n=17) tobramycin concentrations were available. PK parameters were significantly altered post transplant. Elimination rate constant decreased 38% from 0.26±0.1 to 0.16±0.1 h‐1 (P<0.001), with a related increase of 200% in half‐life from 2.8±0.8 to 8.4±8.7 h (P<0.001). Clearance decreased 25% post transplant from 67.3±32.3 to 50.2±15.9 mL/min (P=0.04). No statistically significant change occurred in AUC or Vd after transplant, although a trend was seen toward increased Vd. Dosage requirements after transplantation were significantly lower, 10.7±2.5 and 7.6±1.6 mg/kg/day, pre and post transplant, respectively (P<0.001). Concentrations were also evaluated in 2 time periods: 0–3 weeks and ≥6 weeks post transplant, based on available data. Clearance and Vd ≥6 weeks post transplant did not significantly differ from pre‐transplant values (P=0.28 and 0.54, respectively), suggesting that these changes may be temporary.
Conclusions. The results suggest that tobramycin PK are altered in patients with CF after bilateral lung transplantation, although no clear trend was seen owing to inter‐patient variability. We propose that PK parameters should be reassessed during each treatment course post transplant.</description><identifier>ISSN: 1398-2273</identifier><identifier>EISSN: 1399-3062</identifier><identifier>DOI: 10.1111/j.1399-3062.2011.00651.x</identifier><identifier>PMID: 21794042</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - pharmacokinetics ; cystic fibrosis ; Cystic Fibrosis - drug therapy ; Cystic Fibrosis - surgery ; Female ; Hospitals, Teaching ; Humans ; lung transplant ; Lung Transplantation - physiology ; Male ; pharmacokinetics ; Retrospective Studies ; tobramycin ; Tobramycin - administration & dosage ; Tobramycin - pharmacokinetics</subject><ispartof>Transplant infectious disease, 2011-12, Vol.13 (6), p.616-621</ispartof><rights>2011 John Wiley & Sons A/S</rights><rights>2011 John Wiley & Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4051-9c8bb5d06a755572589baa1a5470f0f19c40e557675a40ecdda739110845b91d3</citedby><cites>FETCH-LOGICAL-c4051-9c8bb5d06a755572589baa1a5470f0f19c40e557675a40ecdda739110845b91d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1399-3062.2011.00651.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1399-3062.2011.00651.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21794042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walsh, K.A.</creatorcontrib><creatorcontrib>Davis, G.A.</creatorcontrib><creatorcontrib>Hayes, D. Jr</creatorcontrib><creatorcontrib>Kuhn, R.J.</creatorcontrib><creatorcontrib>Weant, K.A.</creatorcontrib><creatorcontrib>Flynn, J.D.</creatorcontrib><title>Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation</title><title>Transplant infectious disease</title><addtitle>Transpl Infect Dis</addtitle><description>K.A. Walsh, G.A. Davis, D. Jr Hayes, R.J. Kuhn, K.A. Weant, J.D. Flynn. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation.
Transpl Infect Dis 2011: 13: 616–621. All rights reserved
Study objectives. To compare the pharmacokinetics (PK) of tobramycin in patients with cystic fibrosis (CF) before and after bilateral lung transplantation, in order to evaluate optimal dosing practices post transplant.
Design. Retrospective, single‐center, chart review study, in which tobramycin concentrations from CF patients were used to calculate PK parameters, including elimination rate constant, half‐life, volume of distribution (Vd), area under the curve (AUC), and clearance before and after lung transplantation.
Setting. Medical school‐affiliated teaching hospital.
Patients. Eight patients with CF, who received a bilateral lung transplant from January 1, 2005 through August 1, 2009 (4 males, 4 females; mean age 26.3 years).
Interventions. None.
Main results. Sixty‐nine sets of pre‐ (n=52) and post transplant (n=17) tobramycin concentrations were available. PK parameters were significantly altered post transplant. Elimination rate constant decreased 38% from 0.26±0.1 to 0.16±0.1 h‐1 (P<0.001), with a related increase of 200% in half‐life from 2.8±0.8 to 8.4±8.7 h (P<0.001). Clearance decreased 25% post transplant from 67.3±32.3 to 50.2±15.9 mL/min (P=0.04). No statistically significant change occurred in AUC or Vd after transplant, although a trend was seen toward increased Vd. Dosage requirements after transplantation were significantly lower, 10.7±2.5 and 7.6±1.6 mg/kg/day, pre and post transplant, respectively (P<0.001). Concentrations were also evaluated in 2 time periods: 0–3 weeks and ≥6 weeks post transplant, based on available data. Clearance and Vd ≥6 weeks post transplant did not significantly differ from pre‐transplant values (P=0.28 and 0.54, respectively), suggesting that these changes may be temporary.
Conclusions. The results suggest that tobramycin PK are altered in patients with CF after bilateral lung transplantation, although no clear trend was seen owing to inter‐patient variability. We propose that PK parameters should be reassessed during each treatment course post transplant.</description><subject>Adult</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>cystic fibrosis</subject><subject>Cystic Fibrosis - drug therapy</subject><subject>Cystic Fibrosis - surgery</subject><subject>Female</subject><subject>Hospitals, Teaching</subject><subject>Humans</subject><subject>lung transplant</subject><subject>Lung Transplantation - physiology</subject><subject>Male</subject><subject>pharmacokinetics</subject><subject>Retrospective Studies</subject><subject>tobramycin</subject><subject>Tobramycin - administration & dosage</subject><subject>Tobramycin - pharmacokinetics</subject><issn>1398-2273</issn><issn>1399-3062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUMtuGyEURVGr2En7CxG7rGYCM8MwSN1UbppGslypch87dGGYBHseDmDZ_vsyduJ12NwjzuPCQQhTktJ47lYpzYVIclJmaUYoTQkpGU33F2h6Jj4ccZVkGc8n6Mr7FSGUi0Jcokk2AlJkU9QuB-WgO2jb480zuA70sLa9CVZ7PN5BsKYPHu9seMb64COBG6vc4K3HyjSDMxj6GkMTjMPKthAntLjd9k84OOj9poU-xJih_4Q-NtB68_l1XqPf3--Xsx_J_OfD4-zrPNEFYTQRulKK1aQEzhjjGauEAqDACk4a0lARZSYSJWcQka5r4LmglFQFU4LW-TW6PeVu3PCyNT7Iznpt2vgQM2y9FLRivMoFj8rqpNTxQ96ZRm6c7cAdJCVyrFqu5NioHBuVY9XyWLXcR-vN65Kt6kx9Nr51GwVfToKdbc3h3cFy-fgtgmhPTnbrg9mf7eDWsuQ5Z_Lv4kEuF4t_pPizkL_y_7_2nbI</recordid><startdate>201112</startdate><enddate>201112</enddate><creator>Walsh, K.A.</creator><creator>Davis, G.A.</creator><creator>Hayes, D. Jr</creator><creator>Kuhn, R.J.</creator><creator>Weant, K.A.</creator><creator>Flynn, J.D.</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201112</creationdate><title>Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation</title><author>Walsh, K.A. ; Davis, G.A. ; Hayes, D. Jr ; Kuhn, R.J. ; Weant, K.A. ; Flynn, J.D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4051-9c8bb5d06a755572589baa1a5470f0f19c40e557675a40ecdda739110845b91d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>cystic fibrosis</topic><topic>Cystic Fibrosis - drug therapy</topic><topic>Cystic Fibrosis - surgery</topic><topic>Female</topic><topic>Hospitals, Teaching</topic><topic>Humans</topic><topic>lung transplant</topic><topic>Lung Transplantation - physiology</topic><topic>Male</topic><topic>pharmacokinetics</topic><topic>Retrospective Studies</topic><topic>tobramycin</topic><topic>Tobramycin - administration & dosage</topic><topic>Tobramycin - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walsh, K.A.</creatorcontrib><creatorcontrib>Davis, G.A.</creatorcontrib><creatorcontrib>Hayes, D. Jr</creatorcontrib><creatorcontrib>Kuhn, R.J.</creatorcontrib><creatorcontrib>Weant, K.A.</creatorcontrib><creatorcontrib>Flynn, J.D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplant infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walsh, K.A.</au><au>Davis, G.A.</au><au>Hayes, D. Jr</au><au>Kuhn, R.J.</au><au>Weant, K.A.</au><au>Flynn, J.D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation</atitle><jtitle>Transplant infectious disease</jtitle><addtitle>Transpl Infect Dis</addtitle><date>2011-12</date><risdate>2011</risdate><volume>13</volume><issue>6</issue><spage>616</spage><epage>621</epage><pages>616-621</pages><issn>1398-2273</issn><eissn>1399-3062</eissn><abstract>K.A. Walsh, G.A. Davis, D. Jr Hayes, R.J. Kuhn, K.A. Weant, J.D. Flynn. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation.
Transpl Infect Dis 2011: 13: 616–621. All rights reserved
Study objectives. To compare the pharmacokinetics (PK) of tobramycin in patients with cystic fibrosis (CF) before and after bilateral lung transplantation, in order to evaluate optimal dosing practices post transplant.
Design. Retrospective, single‐center, chart review study, in which tobramycin concentrations from CF patients were used to calculate PK parameters, including elimination rate constant, half‐life, volume of distribution (Vd), area under the curve (AUC), and clearance before and after lung transplantation.
Setting. Medical school‐affiliated teaching hospital.
Patients. Eight patients with CF, who received a bilateral lung transplant from January 1, 2005 through August 1, 2009 (4 males, 4 females; mean age 26.3 years).
Interventions. None.
Main results. Sixty‐nine sets of pre‐ (n=52) and post transplant (n=17) tobramycin concentrations were available. PK parameters were significantly altered post transplant. Elimination rate constant decreased 38% from 0.26±0.1 to 0.16±0.1 h‐1 (P<0.001), with a related increase of 200% in half‐life from 2.8±0.8 to 8.4±8.7 h (P<0.001). Clearance decreased 25% post transplant from 67.3±32.3 to 50.2±15.9 mL/min (P=0.04). No statistically significant change occurred in AUC or Vd after transplant, although a trend was seen toward increased Vd. Dosage requirements after transplantation were significantly lower, 10.7±2.5 and 7.6±1.6 mg/kg/day, pre and post transplant, respectively (P<0.001). Concentrations were also evaluated in 2 time periods: 0–3 weeks and ≥6 weeks post transplant, based on available data. Clearance and Vd ≥6 weeks post transplant did not significantly differ from pre‐transplant values (P=0.28 and 0.54, respectively), suggesting that these changes may be temporary.
Conclusions. The results suggest that tobramycin PK are altered in patients with CF after bilateral lung transplantation, although no clear trend was seen owing to inter‐patient variability. We propose that PK parameters should be reassessed during each treatment course post transplant.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>21794042</pmid><doi>10.1111/j.1399-3062.2011.00651.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1398-2273 |
| ispartof | Transplant infectious disease, 2011-12, Vol.13 (6), p.616-621 |
| issn | 1398-2273 1399-3062 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_918578397 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacokinetics cystic fibrosis Cystic Fibrosis - drug therapy Cystic Fibrosis - surgery Female Hospitals, Teaching Humans lung transplant Lung Transplantation - physiology Male pharmacokinetics Retrospective Studies tobramycin Tobramycin - administration & dosage Tobramycin - pharmacokinetics |
| title | Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A47%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tobramycin%20pharmacokinetics%20in%20patients%20with%20cystic%20fibrosis%20before%20and%20after%20bilateral%20lung%20transplantation&rft.jtitle=Transplant%20infectious%20disease&rft.au=Walsh,%20K.A.&rft.date=2011-12&rft.volume=13&rft.issue=6&rft.spage=616&rft.epage=621&rft.pages=616-621&rft.issn=1398-2273&rft.eissn=1399-3062&rft_id=info:doi/10.1111/j.1399-3062.2011.00651.x&rft_dat=%3Cproquest_cross%3E918578397%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=918578397&rft_id=info:pmid/21794042&rfr_iscdi=true |